Skip to main content
Journal ArticleOPEN ACCESS

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins

  • Ray K
  • Stoekenbroek R
  • Kallend D
  • et al.
Circulation (2018) 138(13) 1304-1316
DOI: 10.1161/circulationaha.118.034710
N/ACitations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Background: The ORION-1 trial (Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol [LDL-C]) demonstrated that inclisiran, an siRNA therapeutic that targets pr...

Cite

CITATION STYLE

APA

Ray, K. K., Stoekenbroek, R. M., Kallend, D., Leiter, L. A., Landmesser, U., Wright, R. S., … Kastelein, J. J. P. (2018). Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins. Circulation, 138(13), 1304–1316. https://doi.org/10.1161/circulationaha.118.034710

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free